Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019

SMi Group8 - 9 April 2019, Boston, USA.
The 6th Annual Pre-Filled Syringes East Coast conference is returning to Boston, USA. The two-day event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

In the run up to the conference, SMi Group caught up with Patrick Gallagher, Business Development Manager, SCHOTT Pharmaceutical Systems, to discuss his upcoming presentation, and his thoughts on the current challenges and opportunities in the pre-filled syringes field.

A snapshot of Patrick Gallagher's interview

Q: The Pre-Filled Syringes market has matured greatly over recent years, what key differences have you noticed in the last year regarding significant developments? A: "In recent years, we have seen quite a bit of interest from pharmaceutical companies to differentiate through delivery device, whether through lifecycle management of a biologic drug into a more complex device or by converting a legacy drug from vial to pre-filled syringe. PFS and cartridge-based primary containers can improve patient safety through less dose preparation and greater ease of use, as well as facilitate the transition of drug administration from a hospital to homecare setting, thus improving patient outcomes."

Q: What do you see as the greatest challenge for you to overcome personally in the pre-filled syringes field at the moment? A: "As an industry, we are still in the early stages of developing connected health solutions and while we are starting to generate significant data it will take some time to best realize how to use this data. Pharma and Medtech companies will need to continue to educate key healthcare stakeholders that device-generated data can improve patient outcomes and drive down healthcare costs."

The full speaker interview and more content including the latest brochure, past attendees list, and other exclusive speaker interviews can be found on the DOWNLOADS section on the website at http://www.pfsamericas.com/pr7

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Novartis and life sciences companies commit expert…

Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics...

Amgen and the Amgen Foundation commit up to $12.5 …

Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in...

AstraZeneca to donate 9 million face masks to supp…

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZ...

Roche response to COVID-19 pandemic

Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic. On March 19, 2020, Roche co...

Singapore modelling study estimates impact of phys…

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (f...

Consignment of 30 million hydroxychloroquine table…

Novartis announced that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Depar...

CAR macrophages go beyond T cells to fight solid t…

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Pere...

FDA approves first plasma therapy for Houston Meth…

Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient i...

Experimental AI tool predicts which COVID-19 patie…

An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study ...

Vivli to launch a portal for sharing data from COV…

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COV...

Roche initiates Phase III clinical trial of Actemr…

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical tria...

Novartis commits to donate up to 130 million doses…

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and...